Nausea is a common symptom of migraine, and current treatment guidelines recommend non-oral formulations for nauseated or vomiting patients. Transdermal delivery of sumatriptan, a 5-hydroxytryptamine1B1D agonist with established efficacy in patients with migraine, represents a novel approach to acute treatment. The sumatriptan iontophoretic transdermal system circumvents the gastrointestinal tract by using low-level electrical energy to transport sumatriptan across the skin. In multiple well-controlled studies, the sumatriptan transdermal system has shown that it provides consistent drug delivery with low interpatient variability, rapid relief of migraine pain and associated symptoms, and an excellent overall safety profile, with a low incidence of triptan-sensation adverse events. Patients and health care professionals who have used the sumatriptan transdermal system give it high ratings for ease of use/application. The sumatriptan transdermal system will allow a wide range of patients, especially those who experience migraine-related nausea or vomiting, to receive the benefits of migraine-specific therapy.Key words: migraine, treatment, sumatriptan, transdermal, gastrointestinal, nausea (Headache 2013;53;S2:34-42) Migraine is a chronic neurologic disorder that affects about 28 million people in the United States 1 with episodic attacks of head pain and some combination of photophobia, phonophobia, nausea, and/or vomiting.2 Although migraine frequency, intensity, and symptomatology tend to vary over time, evidence suggests that about half (49.5%) of patients have migraine-related nausea (MRN) with at least half of their attacks.3 In addition to being a common feature of migraine, frequent MRN has been shown to increase migraine symptom burden and medicationrelated impairment at home, work, and school, as well as in social and leisure activities, 4 and satisfaction with treatment decreases as the frequency of MRN increases.3